ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Amodiaquine Enhances Anti-Melanoma Efficacy of Attenuated Salmonella via Targeting Glutathione Reductase in Neutrophils.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Attenuated Salmonella VNP20009 (VNP) induces significant neutrophil recruitment in the tumor microenvironment (TME) during cancer therapy. However, the exact role of neutrophils in VNP-mediated antitumor effects remains elusive. Here, we first identified the recruited neutrophils as predominantly N2 (pro-tumor) subtype, which remarkably compromised VNP's antitumor efficacy. Therefore, we combined amodiaquine (AQ), known for its neutrophil-inhibiting activity, with VNP treatment to enhance antitumor effects. The combination selectively inhibited TME neutrophils while maintaining favorable biosafety profiles. Employing chemical biology approaches, we identified glutathione reductase (GR) as the key target in neutrophils. Mechanistically, AQ binds to GR and compromises neutrophils' ROS tolerance, leading to selective elimination of neutrophils in the high-ROS TME. A GR-shRNA-loaded VNP strain was further engineered and significantly potentiated VNP's antimelanoma effects. Our work not only advances the understanding of VNP-immune-tumor crosstalk but also provides a potential translational strategy that integrates drug repurposing with synthetic biology for developing microenvironment-smart therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.